Cyclic OmpC peptidic epitope conjugated to tetanus toxoid as a potential vaccine candidate against shigellosis

Jarząb, Anna; Witkowska, Danuta; Ziomek, Edmund; Setner, Bartosz; Czajkowska, Aleksandra; Dorot, Małgorzata; Szewczuk, Zbigniew; Gamian, Andrzej

doi:10.1016/j.vaccine.2018.06.037

Cited by 8 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunization of mice with ompA was found to give protection against a lethal dose of virulent S. flexneri 2a [10]. Meanwhile, previous study also showed that mice immunized with ompC survived after being challenged with live S. flexneri 3a [33], suggesting the OMPs could be one of the ideal components for developing subunit vaccine against shigellosis.…”

Section: Discussionmentioning

confidence: 96%

Reverse vaccinology approach for the identification and characterization of outer membrane proteins of Shigella flexneri as potential cellular- and antibody-dependent vaccine candidates

Leow

Kazi

Ismail

et al. 2020

Clin Exp Vaccine Res

View full text Add to dashboard Cite

In the developing world, bacillary dysentery is one of the most common communicable diarrheal infections. There are approximately 169 million cases of shigellosis reported worldwide. The disease is transmitted by a group of Gram-negative intracellular enterobacteria known as Shigella flexneri, S. sonnei, S. dysenteriae, and S. boydii. Conventional treatment regimens for Shigella have been less effective due to the development of resistant strains against antibiotics. Therefore, an effective vaccine for the long term control of Shigella transmission is urgently needed. Materials and Methods: In this study, a reverse vaccinology approach was employed to identify most conserved and immunogenic outer membrane proteins (OMPs) of S. flexneri 2a. Results: Five OMPs including fepA, ompC, nlpD_1, tolC, and nlpD_2 were identified as potential vaccine candidates. Protein-protein interactions analysis using STRING software (https:// string-db.org/) revealed that five of these OMPs may potentially interact with other intracellular proteins which are involved in beta-lactam resistance pathway. Band T-cell epitopes of the selected OMPs were predicted using BCPred as well as Propred I and Propred (http:// crdd.osdd.net/raghava/propred/), respectively. Each of these OMPs contains regions which are capable to induce Band T-cell immune responses. Conclusion: Analysis acquired from this study showed that five selected OMPs have great potential for vaccine development against S. flexneri infection. The predicted immunogenic epitopes can also be used for development of peptide vaccines or multi-epitope vaccines against human shigellosis. Reverse vaccinology is a promising strategy for the discovery of potential vaccine candidates which can be used for future vaccine development against global persistent infections.

show abstract

Section: Discussionmentioning

confidence: 96%

Reverse vaccinology approach for the identification and characterization of outer membrane proteins of Shigella flexneri as potential cellular- and antibody-dependent vaccine candidates

Leow

Kazi

Ismail

et al. 2020

Clin Exp Vaccine Res

View full text Add to dashboard Cite

show abstract

“…Additionally, splenocytes taken from immunized mice produced significant levels of IFN-γ when stimulated with EpiMix, compared with non-immunized controls. Synthetic epitopes of the OMP OmpC were also evaluated for immunogenicity [54]. Antibody responses to the synthetic linear or cyclic peptides of the main OmpC epitope, conjugated with the tetanus toxoid (TT) as adjuvant, were compared, and there was better recognition of OmpC from antibodies against the cyclic-TT peptides [54].…”

Section: Subunit and Glycoconjugate Vaccinesmentioning

confidence: 99%

Recent Progress in Shigella and Burkholderia pseudomallei Vaccines

et al. 2021

View full text Add to dashboard Cite

Significant advancement has been made in the development of vaccines against bacterial pathogens. However, several roadblocks have been found during the evaluation of vaccines against intracellular bacterial pathogens. Therefore, new lessons could be learned from different vaccines developed against unrelated intracellular pathogens. Bacillary dysentery and melioidosis are important causes of morbidity and mortality in developing nations, which are caused by the intracellular bacteria Shigella and Burkholderia pseudomallei, respectively. Although the mechanisms of bacterial infection, dissemination, and route of infection do not provide clues about the commonalities of the pathogenic infectious processes of these bacteria, a wide variety of vaccine platforms recently evaluated suggest that in addition to the stimulation of antibodies, identifying protective antigens and inducing T cell responses are some additional required elements to induce effective protection. In this review, we perform a comparative evaluation of recent candidate vaccines used to combat these two infectious agents, emphasizing the common strategies that can help investigators advance effective and protective vaccines to clinical trials.

show abstract

“…Recently, it has been reported that a new type of anti-gastrin vaccine using TT as a carrier protein for multiple complex antigens can significantly enhance the immunogenicity of the vaccine (He et al, 2018). Jarzab et al (2018) used TT as the carrier protein for the several synthetic linear or cyclic OmpC epitope peptides and demonstrated that cyclic peptide conjugated to TT as a potential candidate gainst shigellosis. Helper epitopes selected from TTFrC are typically associated with the target epitope to stimulate a CD4 + T cell response (e.g., anti-brucellosis and anti-atherosclerosis multi-epitope vaccines) (Saadi, Karkhah & Nouri, 2017; Tourani, Karkhah & Najafi, 2017).…”

Section: Bacterial Toxin Proteinsmentioning

confidence: 99%

Application of built-in adjuvants for epitope-based vaccines

Yao

Zhao

Shao

et al. 2019

PeerJ

View full text Add to dashboard Cite

Several studies have shown that epitope vaccines exhibit substantial advantages over conventional vaccines. However, epitope vaccines are associated with limited immunity, which can be overcome by conjugating antigenic epitopes with built-in adjuvants (e.g., some carrier proteins or new biomaterials) with special properties, including immunologic specificity, good biosecurity and biocompatibility, and the ability to vastly improve the immune response of epitope vaccines. When designing epitope vaccines, the following types of built-in adjuvants are typically considered: (1) pattern recognition receptor ligands (i.e., toll-like receptors); (2) virus-like particle carrier platforms; (3) bacterial toxin proteins; and (4) novel potential delivery systems (e.g., self-assembled peptide nanoparticles, lipid core peptides, and polymeric or inorganic nanoparticles). This review primarily discusses the current and prospective applications of these built-in adjuvants (i.e., biological carriers) to provide some references for the future design of epitope-based vaccines.

show abstract

Cyclic OmpC peptidic epitope conjugated to tetanus toxoid as a potential vaccine candidate against shigellosis

Cited by 8 publications

References 17 publications

Reverse vaccinology approach for the identification and characterization of outer membrane proteins of Shigella flexneri as potential cellular- and antibody-dependent vaccine candidates

Reverse vaccinology approach for the identification and characterization of outer membrane proteins of Shigella flexneri as potential cellular- and antibody-dependent vaccine candidates

Recent Progress in Shigella and Burkholderia pseudomallei Vaccines

Application of built-in adjuvants for epitope-based vaccines

Contact Info

Product

Resources

About